Drugs / Thymoglobulin
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1/2 | NCT02282514 Background | Oct 2014 → Aug 2019 | classic stiff person syndrome | Northwestern University | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Thymoglobulin | “Thymoglobulin” NCT02282514 ↗ |
| Known as | rATG | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02282514 ↗ |
| Modality | Protein / enzyme biologic | “Rabbit antithymocyte globulin (rATG) (Thymoglobulin®) will be dosed” NCT02282514 ↗ |
| Route | Intravenous | “rabbit anti-thymocyte globulin (thymoglobulin) given intravenously” PMID 33318163 ↗ Dec 2020 |